Misappropriation of Genetic Resources in Africa: A Study of: Pentadiplandra Brazzeana,Impatiens Usambarensis, and Combretum Micranthum by Micalizzi, Julie
Journal of Law, Technology & the Internet · Vol. 8 · 2017 
1 
MISAPPROPRIATION OF GENETIC RESOURCES 
IN AFRICA 
A STUDY OF: PENTADIPLANDRA BRAZZEANA, 
IMPATIENS USAMBARENSIS, AND COMBRETUM 
MICRANTHUM 
Julie Micalizzi 
INTRODUCTION 
The implementation of the patent system sought to foster innovation 
in fields that would yield the most public benefit, by offering the innovator 
an exclusive property right. A patent imparts on its owner a right to exclude 
others from making and distributing the claimed invention. Importantly, a 
patent does not grant the right to make or use the newly claimed invention 
itself, for if the invention is an improvement on a previously patented item, 
the whole item, including the original invention and the improvement as an 
inseparable unit, falls under the umbrella of exclusion associated with the 
original patent. However, the limited property right is generally overcome 
by sophisticated licensing agreements between knowledgeable parties 
wherein the previous patent owner and the owner of the improvement work 
together to allow the other restricted use of each granted right to make an 
item with both attributes. However, this limitation is not to diminish the 
influence of a patented property right alone; in fact, the repercussions of an 
exclusionary right are especially profound regarding misappropriation.  
While the patent system is not meant to reach knowledge already 
within the public domain—since an exclusionary right on natural elements 
would hinder, not promote downstream innovation—the patent system is 
intended to provide avenues of reward for inventions that newly benefit the 
public. Unfortunately, this means that patent system does not reach the entire 
body of information referred to as traditional knowledge, which has been 
discovered and passed down by indigenous groups for generations. Often 
consisting of plants utilized for their flavorful, aesthetic, or medicinal 
qualities, traditional knowledge incorporates mostly natural materials within 
the public domain that indigenous populations utilized for centuries. As 
such, the information is unpatentable. Because traditional knowledge is 
already within the public domain, any patentable “improvements” on the 
traditional knowledge made by third parties would not be considered 
improvements at all, but rather original inventions. Based on the patent 
system, the indigenous groups would not have any initial right to the 
information and would not be entitled to licensing agreements or 
compensation for subsequent inventions. Not only are the traditional groups 
unable to obtain an exclusionary right to the information and prevent others 
from the exploitation and misappropriation of their knowledge, but, 
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furthermore, the indigenous people are also unable to claim any financial 
interest or entitlement to licensing agreements over subsequent research 
done by third parties. 
This paper will address three potential cases of misappropriation 
concerning traditional knowledge and genetic resources of traditional groups 
in Africa and will explore how the Western patent system enabled, 
prevented, and corrected misappropriation in the context of these case 
studies. In all three studies, the patent system failed in misapplying the 
requirements of patentability and in granting patents for information that is 
per se unpatentable. However, the unpatentability of these specific instances 
of traditional knowledge also precludes the indigenous populations from 
claiming property rights over the information. Without an exclusionary 
property right, third parties are still able to commercialize the information. 
While such misappropriation might not be prohibited under patent law, the 
wrongful taking still is immoral. Though the patent system has evolved in 
preventing its inherent discrimination, e.g. recognizing public use outside 
the U.S. as a patent-defeating element, the patent system effectively fails to 
enable the indigenous groups to claim their own property right over the 
information or provide any adequate remedy for the traditional communities 
including recognition or compensation.  
 
I.  TYPES OF MISAPPROPRIATION AND THE PATENT SYSTEM 
 
A. DEFINITION 
While member states in the World Intellectual Property 
Organization (WIPO) do not currently agree upon a definition, Black’s Law 
Dictionary offers one potential understanding of misappropriation: “a 
common-law tort of using the non-copyrightable information or ideas that 
an organization collects and disseminates for a profit to compete unfairly 
against that organization, or copying work whose creator has not yet claimed 
or been granted exclusive rights in work.”1 The elements of misappropriation 
further require: (1) the party claiming right to the information invested time, 
money, or effort for its extraction, (2) the competing party seized the 
information without similar time, money, or effort, (3) and the party claiming 
right to the information thereby suffered injury.2 In the patent context, 
misappropriation involving indigenous populations typically occurs when 
their traditional knowledge—i.e. their unique cultural practices, rituals, and 
traditions—becomes the subject of a patented right by another group that is 
more fiscally and commercially knowledgeable and who retains substantial 
market power or economic influence. Universities and corporations involved 
with pharmaceuticals or biotechnology recognize the monetary potential in 
exploiting certain traditional knowledge and, unrestrained by the patent 
 
1 World Intellectual Property Organization, Glossary, 
http://www.wipo.int/tk/en/resources/glossary.html#33 (last visited April 4, 2017). 
2 Id. 
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system, gain an exclusionary right and effectively engage in 
misappropriation of the claimed information.  
Though the definition of traditional knowledge is also in contention, 
it is often understood as “a living body of knowledge that is developed, 
sustained and passed on from generation to generation within a community, 
often forming part of its cultural or spiritual identity.”3 Furthermore, 
traditional knowledge possesses four general traits that serve as the hallmark 
for the term of art. First, the body of information is all-encompassing 
including knowledge, know-how, rituals, skills, innovations, practices, and 
traditions.4 Traditional knowledge may be cultural and social expressions of 
the indigenous communities—folklore, poetry, music, dance, textiles, 
pottery—or it can pertain to environmental factors, agriculture, or medicine, 
such as therapeutic salves, hunting or fishing techniques, and knowledge 
about animal migration patterns.5 Secondly, indigenous groups serving as 
the guardians of the traditional knowledge passed and continue to pass the 
information between generations and, thirdly, the groups pass the 
information in a traditional, often oral, context.6 Finally, the traditional 
knowledge forms a significant portion of and often defines the lifestyle of 
the indigenous communities who safeguard the information.7  Traditional 
knowledge, for many indigenous communities, “forms part of a holistic 
world-view, and is inseparable from their very ways of life and their cultural 
values, spiritual beliefs and customary legal systems.”8 More than a 
commercial success, a community’s traditional knowledge lies at the heart 
of its very identity.  
Often, traditional knowledge does have a practical element or 
commercial potential as well as public health and entertainment 
implications. As a subset of traditional knowledge, genetic resources may 
offer great benefit to society at large. However, “when others seek to benefit 
from [traditional knowledge], especially for industrial or commercial 
advantage, this can lead to concerns that the knowledge has been 
misappropriated and that the role and contribution of [the traditional 
knowledge] holders has not been recognized and respected.”9 The 
Convention on Biological Diversity defines genetic resources as “parts of 
biological materials that: (1) contain genetic information of value and (2) are 
capable of reproducing or being reproduced.”10 Examples of genetic 
resources include matter isolated from plants, animals, or microbes, 
 
3 Intellectual Property and Genetic Resources, Traditional Knowledge and Traditional Cultural 
Expressions, WIPO Publication No. 933(E), 2015, at 13. 
4 Id. 
5 Id. at 14, 17. 
6 Id. at 13. 
7 Id. 
8 Intellectual Property and Traditional Knowledge, WIPO Publication No. 920(E), 2006, at 1. 
9 Id. 
10 World Intellectual Property Organization, Intellectual Property and Genetic Resources, 
Traditional Knowledge and Traditional Cultural Expressions, WIPO Publication No. 933(E) 1, 18 
(2015) (available at http://www.wipo.int/edocs/pubdocs/en/tk/933/wipo_pub_933.pdf). 
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including medicinal or agricultural crops, and animal breeds.11 It is precisely 
the practicality and usefulness of these genetic resources that render them 
susceptible to commercial exploitation by third parties. Misappropriation 
“entails the wrongful or dishonest use or borrowing of someone’s 
property.”12 Not only does misappropriation prevent indigenous 
communities from claiming a property right to the information they have 
discovered, isolated, and used that now belongs to another entity holding a 
patent to the traditional knowledge, but moreover, misappropriation leaves 
the native groups without any financial ownership of their traditional 
knowledge. The indigenous groups are unable to participate in any of the 
profit that results from the misappropriation of their traditional knowledge. 
Furthermore, as a core element of the group’s identity, taking of their 
traditional knowledge and genetic resources without consent or prospective 
benefit sharing presents not only financial concerns, but moral concerns as 
well. 
Silke von Lewinski, in her book Indigenous Heritage and 
Intellectual Property: Genetic Resources, Traditional Knowledge, and 
Folklore, characterizes traditional knowledge and genetic resources in a 
manner distinct from the definitions heretofore discussed. Where it is 
otherwise understood that both genetic resources and traditional knowledge 
are interrelated and identifiable as property rights, Lewinski distinguishes 
the two domains based on the potential for recognition within the patent 
system.13 Lewinski argues: “Traditional knowledge is human information, 
and as such it can be considered as something ‘intellectual,’ which may lead 
to protection within the framework of intellectual property rights.”14 On the 
other hand, genetic resources “may contain important and useful 
information,” but this information “is merely natural, and therefore in 
principle not ‘intellectual’ information.”15 In essence, intellectual property 
and patent protection for genetic resources is not available by virtue of their 
natural origin—in patentability terms, the material is ineligible subject 
matter. However, such information may yield potential for a property right 
when the natural components are “processed by humans,” e.g., the useful 
compound is investigated, the application proves novel, non-obvious, and 
useful16—the requirements necessary to obtain a U.S. patent. Furthermore, 
where misappropriation of traditional knowledge infringes a property right 
of another, misappropriation of a genetic resource does not carry such a 
violation.17 Instead, as Lewinski contemplates, “the sovereign right in a part 
of biological diversity [that is violated in misappropriation of genetic 
 
11 Id. 
12 Glossary, supra note 1. 
13 See Lewwinski, Silke Von, Indigenous Heritage and Intellectual Property: Genetic Resources, 
Traditional Knowledge, and Folklore 164 (Kluwer Law Int’l, 2004). 
14 ID.  
15 Id. 
16 Id. 
17 Id. at 165. 
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resources], is not an intellectual right, but a material one.”18 
Misappropriation of genetic resources is theft, not infringement of 
intellectual property.19 
The United Nations Conference on Trade and Development offers 
yet another variation on the definition: misappropriation “refers to access to 
and use of genetic resources without prior informed consent and/or mutually 
agreed terms pursuant to the national access legislation of the country 
providing the genetic resources and applicable international rules on access 
and benefit sharing.”20 As an illustration, misappropriation of genetic 
resources may occur by means of the intellectual property system when “a 
company sources biological resources from a country without consent, 
utilizes that resource in [research and development] to develop an invention, 
and then attempts to patent that invention utilizing the resource without any 
benefits to the provider, or without mentioning where the resource was 
obtained.”21 Similar to Lewinski’s definition above, misappropriation of 
genetic resources only becomes relevant in regards to intellectual property 
rights after research, isolation, development, and usefulness—effectively 
bringing the material within the purview of patentability. However, as will 
be discussed in the following section, once the material becomes patentable 
in the sense of novelty and nonobviousness, wherein research and 
development takes the ineligible subject matter of plants and naturally-
occurring information and transforms it into an invention, such 
distinguishing features, under U.S. patent law, render the end-result the 
intellectual property of the inventor. Indigenous groups would not have a 
claim for intellectual property rights because: (1) the original traditional 
knowledge is unpatentable and (2) the final information that is patentable is 
characteristically different from the original source material.  Importantly, 
however, the UN conference suggests potential solutions to the problem of 
misappropriation, which would be at least morally acceptable in the event 
the law precludes remedy, informed consent, plans of access and benefit 
sharing, and disclosure of sourcing. 
Even news sites have acknowledged and attempted to define 
misappropriation in the context of genetic resources; Anthony Barnett 
comments that the term biopiracy “is being increasingly used by 
environmental groups to describe a new form of "colonial pillaging" in 
which western corporations reap profits by taking out patents on indigenous 
materials from developing countries and turning them into lucrative 
products.”22 However, as Barnett recognizes, the corporations rarely share 
benefits of such commercialization with the country of origin23—one of the 
 
18 Id. 
19 See id. 
20 U.N. CONFERENCE ON TRADE AND DEV., THE CONVENTION ON BIOLOGICAL DIVERSITY AND THE 
NAGOYA PROTOCOL: INTELLECTUAL PROPERTY IMPLICATIONS 1 (2014). 
21 Id. 
22 Anthony Barnett, Biopiracy in Africa, THE GUARDIAN, Sept. 22, 2006, 
http://www.theguardian.com/world/2006/sep/22/outlook.development. 
23 See id. 
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many characteristics of misappropriation that seems to evoke not only 
financial and property concerns, but also moral implications. 
B. PATENT SYSTEM 
For an invention to receive a patent right in the U.S., the invention 
must pertain to eligible subject matter24 and must be novel,25 non-obvious,26 
and useful.27 However, even with requirements that would suggest a narrow 
scope for patent eligible inventions, the U.S. definitions of prior art, public 
use, and inventive step effectively broaden the application of patent laws and 
enable the misappropriation of traditional knowledge and genetic resources 
of other countries. Additionally, often it is the case that the requirements for 
patentability are misapplied to a specific situation yielding patents that 
should not have been granted at all, i.e. in respect to naturally occurring 
plants and nucleotide sequences or well-known uses and applications of 
medicinal herbs. In these instances where public use, printed publications, 
and ineligible subject matter should have precluded patentability, the 
indigenous peoples who have held the traditional knowledge and genetic 
resources would also have been prevented from receiving patent protection. 
Furthermore, in instances where the patent-holders have transformed 
naturally-occurring and ineligible subject matter into a novel and 
nonobvious invention, the indigenous groups would still not have a legal 
intellectual property right claim to the invention. Such wrongful taking, 
though not prohibited under the patent legal system, might still elicit a moral 
claim to compensation or recognition. 
1. ELIGIBLE SUBJECT MATTER—ISOLATION OF 
ACTIVE INGREDIENTS 
When determining what constitutes eligible subject matter, courts 
look to 35 U.S.C. §101 which provides, “whoever invents or discovers any 
new and useful process, machine, manufacture, or composition of matter, or 
any new and useful improvement thereof, may obtain a patent therefor, 
subject to the conditions and requirements of this title.”28 Although hallmark 
cases regarding eligible subject matter, Diamond v. Chakrabarty and 
Association for Molecular Pathology v. Myriad Genetics, Inc., reaffirmed 
patent law’s general principle that naturally-occurring material is 
unpatentable, the case studies discussed later in this paper demonstrate that 
these court rulings might have been misapplied and resulted in the wrongful 
granting of property rights over natural proteins and plants. 
 
24 35 U.S.C. § 101 (2013). 
25 See 35 U.S.C. § 102 (2013). 
26 See 35 U.S.C. § 103 (2013). 
27 35 U.S.C. § 101 (2013). 
28 See id.  
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While Myriad is a newer case decided only in 2013, Chakrabarty 
has been U.S. precedent since 1980. In Chakrabarty, the Supreme Court of 
the U.S. held that human-made genetically engineered bacterium capable of 
breaking down crude oil was an invention eligible for patentability because: 
(1) it was not naturally occurring29 and (2) had possessed characteristics 
markedly different from naturally-occurring bacterium that were direct the 
result of human ingenuity.30Since the 1930 Plant Patent Act, crossing two 
plant varieties when the resulting hybrid does not occur naturally has 
expressly enabled the patentability of plants that are asexually produced, 
according to Congress.31 Additionally, under the World Trade Organization 
agreement on Trade-Related Intellectual Property Rights, “it is possible to 
patent life forms if they have been altered in some way for new and 
innovative uses.”32 In Myriad, the U.S. Supreme Court further refined this 
principle by holding that a naturally-occurring nucleotide DNA sequence is 
not patentable because of its isolation from the full DNA molecule. DNA, 
containing only the protein-coding genes and ability to be produced only in 
a laboratory setting, however, remains patent-eligible.33 The difference again 
lies in the definitions of naturally-occurring matter and human invention. 
Importantly, Myriad expressly outlines what the decision did not seek to 
resolve—patents claiming novel methods of manipulating genes, new 
applications of knowledge regarding genes, and the patentability of DNA 
wherein scientists alter the naturally-occurring nucleotide sequence34—
which is the subject of one of the following case studies. 
Patent law intends to promote creation and allow public access to 
critical inventions, while incentivizing and compensating the inventors with 
a temporary exclusionary property right. However, patent law is hesitant to 
upset the principle that laws of nature, natural phenomena, and abstract ideas 
are not patentable. Not only is this information already within the public 
domain, even if not yet isolated or named, but it also ties-up potential 
downstream innovations. In short, Chakrabarty created a new bacterium 
whereas Myriad created nothing. While Myriad’s discovery and isolation of 
genes related to breast cancer required much effort and resulted in 
information highly significant and sought after, it is simply not eligible for 
patent protection. 
2. NOVELTY—PRIOR ART AND PRIOR USE 
 
29 Diamond v. Chakrabarty, 447 U.S. 303, 305 (1980). 
30 Id. at 310. 
31 Id. at 312. 
32 Marilyn Carr & Martha Alter Chen, Globalization and the Informal Economy: How Global Trade 
and Investment Impact on the Working Poor, Women in Informal Employment Globalizing & 
Organizing 1, 19 (2001) (available at http://natlex.ilo.ch/wcmsp5/groups/public/---
ed_emp/documents/publication/wcms_122053.pdf). 
33 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2111 (2013). 
34 Id. at 2119-20. 
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The requirement of novelty for patents filed on or after March 16, 
2013 is disclosed in post-AIA 35 U.S.C. § 102(a):  
A person shall be entitled to a patent unless— (1) the 
claimed invention was patented, described in a printed 
publication, or in public use, on sale, or otherwise available 
to the public before the effective filing date of the claimed 
invention; or (2) the claimed invention was described in a 
patent issued under section 151, or in an application for 
patent published or deemed published under section 
122(b).35  
 
Thus, all material and knowledge within the public domain, through either 
printed-publication or public-use for more than 1 year,36 is unpatentable 
regardless of geographical location. As written, this would prevent U.S. 
companies and universities from exploiting indigenous groups’ traditional 
knowledge and genetic resources. At the same time, these limitations would 
also prevent the indigenous groups from obtaining a patent of material 
disclosed in a printed publication or in public-use for more than one year. 
However, novelty pre-AIA included geographical limitations such 
that: “A person shall be entitled to a patent unless (a) the invention was 
known or used by others in this country, or patented or described in a printed 
publication in this or a foreign country, before the invention thereof by the 
applicant for a patent.”37 Thus, to defeat patent eligibility, prior art outside 
of the U.S. must be contained in a printed publication whereas within the 
U.S. the prior art need only be in public use. Thus, U.S. patent law pre-AIA 
purported to protect oral traditional knowledge and genetic resources only if 
it were present in the U.S., presumably that of Native Americans. However, 
patent law failed to provide adequate means of protection for the oral 
traditional knowledge and genetic resources of indigenous groups outside of 
the U.S. where the material had not been published in a printed publication, 
or if the material had been published, was not widely available or searchable. 
The requirement of pre-AIA novelty especially discriminated “against 
indigenous communities in other countries because their knowledge is rarely 
documented.”38 In fact, per the four qualities generally characteristic of 
traditional knowledge, such indigenous groups generally pass down their 
traditional knowledge in an oral, and not written, context. 
3. NONOBVIOUSNESS—INVENTIVE-STEP 
The requirement of nonobviousness for patents filed before March 
16, 2013 is disclosed in pre-AIA 35 U.S.C. §103(a):  
 
35 35 U.S.C. § 102(a) (2013) (post-AIA). 
36 35 U.S.C. § 102(b) (2013) (post-AIA). 
37 35 U.S.C. § 102(a) (1952) (pre-AIA). 
38 Lakshmi Sarma, Note & Comment: Biopiracy: Twentieth Century Imperialism in the Form of 
International Agreements, 13 TEMP. INT’L & COMP. L.J. 107, 130 (1999). 
Journal of Law, Technology & the Internet · Vol. 8 · 2017  
Misappropriation of Genetic Resources in Africa 
9 
A patent may not be obtained though the invention is not 
identically disclosed or described as set forth in section 102 
, if the differences between the subject matter sought to be 
patented and the prior art are such that the subject matter as 
a whole would have been obvious at the time the invention 
was made to a person having ordinary skill in the art to 
which said subject matter pertains. Patentability shall not 
be negated by the manner in which the invention was 
made.39  
 
After the AIA, the change to the language of §103(a) was minimal, reflecting 
the change from first-to-invent to first-to-file such that the timeframe is not 
at the time the invention was made, but rather, “before the effective filing 
date of the claimed invention.”40 
Whereas novelty sought to assure that patents were not granted for 
information and material already within the public domain, nonobviousness 
demands the invention be sufficiently removed from prior art—a leap 
forward or an inventive step. In Mayo Collaborative Services v. Prometheus 
Laboratories, Inc., the Supreme Court of the U.S. held that in order to 
overcome nonobviousness, there must be an inventive concept “sufficient to 
ensure that the patent in practice amounts to significantly more than a patent 
upon the natural law itself.”41 In Graham v. John Deere Co., the U.S. 
Supreme Court described a test to determine nonobviousness: ascertaining 
the scope and content of the prior art, the differences between the prior art 
and the claims at issue, and the level of ordinary skill in the pertinent art.42 
The requirement of obviousness is intended to ensure “whether the subject 
matter sought to be patented and the prior art are such that the subject matter 
as a whole would have been obvious at the time the invention was made to a 
person having ordinary skill in the art to which said subject matter 
pertains.”43 Furthermore, secondary considerations such as commercial 
success, long-felt but unresolved needs, and failure of others may aid in the 
nonobviousness determination.44 
Importantly, nonobviousness looks to the direction of the prior art 
and is determined in reference to a person having ordinary skill in the art. In 
United States v. Adams, the U.S. Supreme Court held the patent valid and 
nonobvious because the prior art—suggesting that water-activated batteries 
were successful only when combined with electrolytes detrimental to the use 
of magnesium— taught away from the invention.45 The invention at issue 
utilized cuprous chloride, which has an interdependent relationship with 
 
39 35 U.S.C. §103(a) (1952) (pre-AIA).  
40 35 U.S.C. §103(a) (2013) (post-AIA). 
41 Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1294 (2012). 
42 Graham v. John Deere Co. of Kan. City, 383 U.S. 1, 17 (1966). 
43 Id. at 3. 
44 Id. at 17. 
45 United States v. Adams, 383 U.S. 39, 52 (1966). 
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magnesium.46  On the other hand, as an example of obviousness, in Hotchkiss 
v. Greenwood, the U.S. Supreme Court held the substitution of clay or 
porcelain in doorknobs where the prior art disclosed use of metallic knobs 
was obvious and not patentable.47 The Court determined the improvement 
was the work of a mechanic and not an inventor:  
Unless more ingenuity and skill in applying the old method 
of fastening the shank and the knob were required in the 
application of it to the clay or porcelain knob than were 
possessed by an ordinary mechanic acquainted with the 
business, there was an absence of the degree of skill and 
ingenuity which constitute essential elements of every 
invention.48  
 
To determine who constitutes a person of ordinary skill in the art, the Federal 
Circuit offered several factors in their decision for Daiichi Sankyo Co, LTD 
v. Apotex Inc., including: the educational level of the inventor, the type of 
problems encountered in the art, prior art solutions to those problems, 
rapidity with which innovations are made, sophistication of the technology, 
and educational level of active workers in the field.49 
The intent of patentability requirements is to ensure information 
already within the public realm or already utilized by groups of people are 
not wrongfully taken and exploited by entities with greater financial 
resources and commercial market power. The requirements, however, 
effectively preclude indigenous groups from claiming intellectual property 
rights to their traditional knowledge and genetic resources. Such traditional 
knowledge and genetic resources are often undocumented, in public-use for 
generations, and typically encompass natural materials. Interestingly, as the 
following three case studies illustrate, much of the misappropriation does not 
occur as the exploitation of patentable indigenous knowledge; rather, 
misapplication of the patentability requirements accounts for much of the 
failure of the patent system to protect the indigenous groups’ traditional 
knowledge and genetic resources. Of course, this again precludes the 
indigenous groups themselves from claiming intellectual property rights of 
their traditional knowledge and genetic resources when it is naturally 
occurring, previously published, in public use, or utilized as a source for a 
patentable invention that is markedly different from the original material. 
Thus, to curtail misappropriation, the patent system must be reorganized so 
as to protect a special subset of public knowledge when that public is an 
indigenous group. 
 
II. CASE STUDY I: PENTADIPLANDRA BRAZZEANA 
 
46 Id. at 50. 
47 Hotchkiss v. Greenwood, 52 U.S. (11 How.) 248, 264 (1851). 
48 Id. at 267. 
49 Daiichi Sankyo Co., Ltd. v. Apotex, Inc., 501 F.3d 1254, 1256 (Fed. Cir. 2007). 
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The West African plant pentadiplandra brazzeana, the fruit of 
which Gabon locals refer to as j’oublie,50 is host to the protein brazzein 
reported to be 500 to 200051 times sweeter than sugar.52 Recognizing the 
commercial market-potential for low-calorie sugar alternatives in a country 
plagued by obesity, the University of Wisconsin-Madison through its 
Wisconsin Alumni Research Foundation (WARF) sought to harness the 
concentrated sugar-like sweetness and low-glycemic qualities of brazzein.53 
While WARF recognizes that traditional communities indigenous to the 
region of natural growth have consumed the berries associated with 
pentadiplandra brazzeana “for thousands of years,”54 WARF holds 
numerous patents associated with brazzein and claims the protein as “an 
invention of UW-Madison research.”55 At the same time, despite the well-
established documentation of the traditional communities in Gabon use of 
brazzein, it does not appear that a specific traditional community, 
organization, or government within West Africa has claimed the use of 
j’oublie as their intellectual property, or specifically accused WARF of 
misappropriation. Since the concept of misappropriation implies that a 
traditional community has asserted rights over the traditional knowledge and 
deems the use of the materials as a taking, without such knowledge of who 
is harmed, it would be difficult for WARF to obtain prior informed consent 
or engage in access and benefit-sharing. At the same time, perhaps without 
knowledge of their own exploitation, it might be impossible for an 
indigenous group to alert WARF and other institutions to the perceived 
misappropriation. 
In the 1980s, ethnobotanist Claude-Marcel Hladik, utilizing 
information a Gabonese assistant provided him, supplied UW-Madison 
researcher Göran Hellekant with berries from pentadiplandra brazzeana, 
urging him to study their sweet quality. 56 Upon watching natives of the 
region eat the j’oublie berries, researcher Hellekant allegedly decided, “there 
 
50 Robert Ostergard et al., Between the Sacred and the Secular: Indigenous Property, International 
Markets, and the Modern African State, 44 THE J. OF MOD. AFR. STUD. 309, 317 (2006). 
51 Julia Rojahn, Fair Shares or Biopiracy: Developing Ethical Criteria for the Fair and Equitable 
Sharing of Benefits from Crop Genetic Resources, EBERHARD KARLS UNIVERSITÄT TÜBINGEN 1, 15 
(2010) (available at http://d-nb.info/1001988825/34). 
52 Magdalena Kaihuzi, LDCs in a Globalizing World: A Strategy for Gender-Balanced Sustainable 
Development, in United Nations Conference on Trade and Development: Trade, Sustainable 
Development and Gender  347, 356 (1999) (available at 
http://unctad.org/en/docs/poedm_m78.en.pdf). 
53 Variants of the Sweet Protein Brazzein with Improved Characteristics, Wisconsin Alumni 
Research Foundation, 1,1 (available at https://www.warf.org/documents/technology-
summary/P02087US.pdf). 
54 Natur Research Ingredients to Launch Cweet™ New Natural Intense Sweetener Worldwide, 
Wisconsin Alumni Research Foundation (Nov. 5, 2007), http://www.warf.org/news-
media/news/releases-and-announcements/natur-research-ingredients-to-launch-cweet-new-natural-
intense-sweetener-worldwide.cmsx. 
55 Kaihuzi, supra note 51 at 356. 
56 Baruch A. Brody, Intellectual Property, State Sovereignty, and Biotechnology, 20 KENNEDY INST. 
OF ETHICS J. 51, 53 (2010).  
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was something of value there.”57 Between 1989 and 1994, Hellekant and the 
UW-Madison researchers discovered the sweetness of the fruit was of a 
proteinaceous nature,58 isolated the protein through purification and named 
it brazzein, and identified its naturally occurring amino acid sequence.59 
Results of the targeted research indicated lucrative physical and molecular 
qualities that suggest the protein would be promising as a sugar substitute—
its solubility in water and heat stability, its sweetness profile that is very 
close to sucrose, its low glycemic index and low caloric nature, and its lack 
of aftertaste that is a lingering side effect characteristic of most other sugar 
substitutes.60 Beginning in 2003, Hellekant and fellow researchers from 
UW-Madison began to create mutants of the brazzein protein consisting of 
varying amino acid sequences to determine critical regions responsible for 
the overall sweetness of the molecule61 and confirmed the results by studying 
electrophysiological responses in rhesus monkeys and human 
psychophysical to the mutant proteins.62 Studies determined that different 
mutations at specific positions made the new protein either significantly 
sweeter than wildtype brazzein or removed its sweetness altogether.63 
In their publications, the researchers only vaguely disclosed the 
geographical source of the samples analyzed to isolate and research brazzein 
and failed to describe how the samples were actually acquired including any 
permissions gained by government or traditional groups:    
In the 1980s, our attention was attracted to a West African 
plant, Pentadiplandra brazzeana (Hladik et al., 1984). We 
obtained a small sample of smoke-dried berries in which 
we tentatively identified a sweet tasting protein, pentadin 
(van der Wel et al., 1989). From a new and fresher sample 
of the berries’ pulp we identified and isolated the major 
sweet principle of P. brazzeana, which we named brazzein 
(Ming and Hellekant, 1994).64 
 
 
57 Trade Related Intellectual Property Rights (TRIPs) and Farmers’ Rights, UK Parliament (1999) 
(available at 
http://www.publications.parliament.uk/pa/cm199900/cmselect/cmenvaud/45/45ap08.htm). 
58 H. van der Wel et al., Isolation and Characterization of Pentadin, the Sweet Principle of 
Pentadiplandra brazzeiana Baillon, 14 CHEM. SENSES 75,75 (1989). 
59 Ding Ming & Göran Hellekant, G. Brazzein, a New High-Potency Thermostable Sweet Protein 
from Pentadiplandra brazzeana B., 355 FEBS LETTER 106, 106 (1994). 
60 Wisconsin Alumni Research Foundation, supra note 53. 
61 Zheyuan Jin et al., Critical Regions for the Sweetness of Brazzein, 544 FEBS LETTERS 33, 33 
(2003).  
62 Zheyuan Jin et al., Monkey Electrophysiological and Human Psychophysical Responses to 
Mutants of the Sweet Protein Brazzein: Delineating Brazzein Sweetness, 28 CHEM. SENSES 491, 491 
(2003). 
63 Id. 
64 Göran Hellekant & Vicktoria Danilova, Brazzein a Small, Sweet Protein: Discovery and 
Physiological Overview, 30 CHEM. SENSES i88, i88 (2005). 
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In what appears to be the first publication in the series of scientific papers 
that would eventually lead to the isolation and study the specific protein 
brazzein, Hladik describes the initial finding of Central African plants.65 
Though written in French, a crude translated abstract describes the 
geographical source of the study: “The different species of rain-forest plants 
developing starchy tubers were studied around Makokou (N.E. Gabon) and 
in the Lobaye River district (S.W. Central African Republic).”66 Without a 
complete English translation, it is unknown whether Hladik interacted with 
the traditional communities of Gabon and Central Africa during the initial 
survey of the land and the acquisition of the berries. In subsequent 
publications, the researchers, including Hladik and Hellekant, refer to the 
initial procurement of the berries: “The fruits were collected in Gabon 
(voucher specimen in the Paris Herbarium: A.Hladik no. 4139),”67 but again 
fail to specifically describe permissions and interactions with local 
communities. As a trend, in another subsequent scientific publication, the 
researchers disclose the source of the materials by a quick and vague 
reference to geographic location: “Fruits of Pentadiplandra brazzeana from 
West Africa were used.”68 
Importantly, however, Hellekant does acknowledge that the sweet 
properties of j’oublie were well-known to the traditional groups of West 
Africa and Gabon: “Indigenous people have known brazzein for centuries. It 
is consumed either raw or in a cooked form (Hladik and Hladik, 1988) and 
used as a sweetening agent in drinks and food.”69 Furthermore, Hladik and 
Hellekant recognize that the very basis of their study, the sweet nature of 
brazzein, has been well-known by traditional communities of the area: 
“Under a thick epicarp, these berries contain one to five reniform seeds 
surrounded by a thick soft layer of red pulp which is locally known, 
especially in Gabon, for its strong sweet taste.”70  Even with this recognition, 
Hellekant and the University of Wisconsin-Madison claim the discovery of 
the sweet protein brazzein as a result of their own scientific research and 
study: “We have discovered a new high-potency thermostable sweet protein, 
which we name brazzein, in a wild African plant Pentadiplandra 
brazzeana.”71 
Resulting from UW-Madison’s extensive research into the brazzein protein, 
WARF has acquired eight utility U.S. patents,72 two patents granted by 
 
65 Annette Hladik et al., Les plantes `a tubercules de la forˆet dense d’Afrique Centrale. 39 Revue 
d’Ecologie (Terre et Vie) 249 (1984) (available at 
http://documents.irevues.inist.fr/handle/2042/55168). 
66 Id. 
67 van der Wel, supra note 57 at 75.  
68  Ming, supra note 58 at 106.  
69 Hellekant, supra note 63 at i88. 
70 van der Wel, supra note 57 at 75.  
71 Ming, supra note 58 at 106. 
72 U.S. Patent No. 8,501,910 (active until 2028); U.S. Patent No. 7,812,122 (active until 2029); U.S. 
Patent No. 7,153,535 (expired due to nonpayment of fees); U.S. Patent No. 6,274,707 (expired due 
to nonpayment of fees); U.S. Patent No. 5,741,537 (expired lifetime 1995); U.S. Patent No. 
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Germany, and two from South Africa.73 Of the U.S. patents, four expired due 
to passing of the 20-year term, two expired due to nonpayment of fees, and 
two remain active for at least another 10 years.74 The patents claim a variety 
of structures and uses including: the isolated protein containing the naturally 
occurring amino acid sequence,75 the recombinantly produced protein,76 the 
isolated DNA sequence that codes for the protein,77 a method of increasing 
the sweetness of the protein by altering the amino acid sequence,78 use of 
brazzein as a sweetener in foods and beverages,79 mixing the brazzein 
sweetener with other sweeteners,80 and multiple synthetically created protein 
mutations wherein the amino acid sequence of the naturally-occurring 
brazzein are altered manually thereby changing the sweetness.81  
 
5,527,555 (expired lifetime 1994); U.S. Patent No. 5,346,998 (expired lifetime 1993); U.S. Patent 
No. 5,326,580 (expired lifetime 1993). 
73 S. Afr. Patent No. 1994/01061 and S. Afr. Patent No. 1995/03888. 
74 '910 Patent; '122 Patent; '535 Patent; '707 Patent; '537 Patent; '555 Patent; '998 Patent; '580 Patent 
. 
75 '580 Patent (“A sweet protein containing an amino acid sequence substantially the same as that 
shown in SEQ ID NO:1, the protein being essentially free of Pentadiplandra brazzeana plant material 
other than Brazzein”).  
76 '580 Patent (“A sweet protein containing an amino acid sequence substantially the same as that 
shown in SEQ ID NO:1, wherein the protein has been produced recombinantly and is essentially free 
of Pentadiplandra brazzeana plant material other than Brazzein”); '555 Patent (“A sweet protein 
containing an amino acid sequence according to SEQ ID NO:4 amino acid residues 2-54, wherein 
the protein has been produced recombinantly and is essentially free of Pentadiplandra brazzeana 
plant material other than Brazzein”). 
77 '998 Patent (“The DNA sequence essentially according to SEQ ID NO: 2, wherein the DNA 
sequence is located outside of a Pentadiplandra brazzeana Baillon cell, and the DNA sequence codes 
for essentially the protein of SEQ ID NO: 1, wherein the DNA sequence is essentially free of 
Pentadiplandra brazzeana plant material other than Brazzein”); '555 Patent (“A DNA sequence 
according to SEQ ID NO:5 bases 4-162, wherein the DNA sequence is located outside of a 
Pentadiplandra brazzeana Baillon cell, and the DNA sequence encodes the protein of SEQ ID NO:4 
residues 2-54, wherein the DNA sequence is essentially free of Pentadiplandra brazzeana plant 
material other than Brazzein”). 
78 '537 Patent (“A method of increasing the sweetness of a composition selected from the group 
consisting of foods and beverages comprising the step of adding a sufficient amount of Brazzein 
protein to the composition, so that the composition has an increased sweetness, wherein the Brazzein 
protein has been produced in a recombinant host cell and said protein has been isolated”). 
79 Id. (A composition comprising a food or beverage and a Brazzein protein produced and isolated 
from a recombinant host cell). 
80 '555 Patent (“A composition comprising the protein of claim 1 mixed with another sweetener 
obtained from other than Pentadiplandra brazzeana Baillon”). 
81 '707 Patent (“A synthetically produced peptide having a different sweetness potency or sweetness 
temporal profile from naturally occurring Brazzein comprising an amino acid sequence selected from 
the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 
6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID 
NO: 14”); '535 Patent (“A synthetically produced peptide having a different sweetness potency from 
naturally occurring Brazzein, comprising an amino acid sequence selected from the group consisting 
of SEQ ID NO: 3 and SEQ ID NO: 5”); '122 Patent (“A peptide consisting of: SEQ ID NO: 2 wherein 
the Xaa at position 53 is selected from the group consisting of Phe, Trp or His; SEQ ID NO: 3 
wherein the Xaa-Xaa at positions 1 and 2 is selected from Ile-Ile or Gly-Pro; wherein the peptide has 
a different sweetness potency from naturally occurring Brazzein”); '910 Patent (“A peptide having a 
different sweetness potency from naturally occurring Brazzein, comprising the amino acid sequence 
of SEQ ID NO: 2 where Xaa is not Tyr”). 
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Subsequent work for the UW-Madison has focused on eliminating 
the need to collect the berries from pentadiplandra brazzeana in West 
Africa, instead has enabled the production of brazzein in laboratories by 
means of transgenic organisms.82 In 1998, UW-Madison sold exclusive 
rights for the use of brazzein as an extracted sweetener, however produced, 
to NeKtar Worldwide, who intended to extract large quantities of the protein 
from corn maize genetically modified to express brazzein.83 In a press 
release, NeKtar and ProdiGene announced their promising partnership in a 
lucrative commercial market for sugar alternatives.84 President and CEO of 
NeKtar described: “Since this natural, plant-based sweetener can be 
extracted from corn in a conventional milling operation while preserving the 
value of the other corn products, Brazzein is expected to be extremely cost-
effective to produce.”85 Interestingly, the press release acknowledged the 
general source of the critical protein and the traditional knowledge of the 
berry as a sweetener: “The Brazzein protein is from a West African plant 
where it has been consumed locally for many years.”86 Without much other 
press after 1998, it would appear that the ProdiGene incident wherein the 
biotech company was required to pay millions of dollars for contamination 
of conventional crops, might have halted the production of brazzein.87 
In 2007, UW-Madison granted American corporation Natur 
Research Ingredients exclusive license88 to manufacture and distribute a 
brazzein-based substitute sweetener under the trademark Cweet.89 As of 
April 7, 2016, Cweet has yet to offer a commercially available brazzein 
product for consumer purchase.90 Nevertheless, Cweet hosts a website 
describing the benefits of sugar alternatives derived from brazzein including 
its zero-calorie nature, low glycemic index, similarity to sucrose, and heat 
stability.91 Furthermore, Cweet itself acknowledges the source of its product 
and the traditional knowledge of indigenous groups that encompassed its 
sweetness, “derived from brazzein, a protein extracted from the West 
African fruit of the climbing plant Oubli (pentadiplandra brazzeana 
 
82 Fariba M. Assadi-Porter et al., Brazzein, a Small, Sweet Protein: Effects of Mutations on its 
Structure, Dynamics and Functional Properties, 30 CHEM. SENSES i90, i90 (2005).  
83 Biopiracy, RAFI’s Sixth Annual Update (Rural Advancement Foundation International 
Communique) May/June 2000 at 1, 3 (available at 
http://www.etcgroup.org/files/publication/327/01/com_biopiracy.pdf). 
84 NeKtar Worldwide and ProdiGene to Develop Natural Intense Sweetener in Corn, SeedQuest 
(Seed Quest) April 22, 1998  (available at 
http://www.seedquest.com/News/releases/usa/ProdiGene/N1641.htm.) 
85 Id.  
86 Id. 
87 See Generally Jeffrey Fox, Puzzling Industry Response to ProdiGene Fiasco, 21 NATURE 
BIOTECHNOLOGY 1, 3-4 (2003).  
88 Wis. Alumni Res. Foundation, Exclusive License Agreement Template, (2015) (available at 
http://www.warf.org/media.acux/627e8a4b-6170-4bf1-a50f-ae35bfa7cdb1). 
89 Wis. Alumni Res. Foundation, supra note 53. 
90 Telephone Interview with Stephen Felderstein, Vice President National Sales, Natur Research 
Ingredients, (April 7, 2016).   
91 Cweet Natur Research Ingredients, Cweet Natural Intense Sweetener Attributes, 
http://www.cweet.com/attributes.html (last visited Apr. 6, 2017). 
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Baillon), which has been consumed by local natives…for centuries.”92 
Though the website claims “Cweet” is a registered trademark of Natur 
Research Ingredients,93 a search completed through the USPTO website on 
April 7, 2016 finds that the trademark for “Cweet” is dead by cancellation as 
of February 20, 2015.94 
With a U.S. sweetener market that exceeds $2 billion and annual 
world-wide sales that top $100 billion, the economic implications for a new 
sweetener are vast.95 UW-Madison does not have any plans for access and 
benefit-sharing with the traditional communities in West Africa and Gabon 
who first utilized pentadiplandra brazzeana berries for their unique 
sweetness.96 The traditional groups have not received any compensation for 
use of their traditional knowledge and genetic resources.97 However, Loren 
Miles, CEO of Natur Research Ingredients, Inc., has stated that “because the 
brazzein plant is native to Africa, we are exploring establishing a foundation 
that will contribute to humanitarian causes in Africa once production and 
distribution has started.”98 Still, neither the UW-Madison nor ProdiGene 
recognize any intellectual or material property claim that the Gabonese 
people may have to the use of brazzein as a sugar substitute.99 
Since all of the patents were filed prior to March 16, 2013, the 
relevant statutes that apply are pre-AIA. Under the novelty requirement then, 
prior public use by traditional groups in Gabon and other areas of Africa 
would not defeat the property right of UW-Madison as it did not occur within 
the U.S. Furthermore, since there is no evidence the traditional knowledge 
was written in any sort of printed publication, brazzein would satisfy the 
requirement of novelty. However, if these patents were to have been sought 
after the AIA was passed into law, then the traditional communities could 
have defeated the patent by showing of public use since the AIA eliminates 
the geographical restriction. Still, this change does not necessarily enable the 
traditional groups themselves to claim exclusive patent rights over the 
sweetness of brazzein. If the public use occurred for more than a year prior 
to filing of a patent, which is required in the definition of traditional 
knowledge to have been passed through generations, then those who have 
utilized the material as a part of their traditional knowledge and genetic 
resources for centuries would additionally fail to satisfy the novelty 
requirement of patentability. Therefore, though UW-Madison would be 
unable to gain a patent over the knowledge, the researches and university 
 
92 Cweet Natur Research Ingredients, Cweet Natural Intense Sweetener About, 
http://www.cweet.com/about.html (last visited Apr, 6, 2017). 
93 Cweet Natur Research Ingredients, Cweet Natural Intense Sweetener, http://www.cweet.com/ 
(last visited Apr. 6, 2017).   
94 USPTO. Trademark Electronic Search System (TESS). April 7, 2016. Serial Number 78829311. 
http://tsdr.uspto.gov/#caseNumber=78829311&caseSearchType=US_APPLICATION&caseType=
DEFAULT&searchType=statusSearch 
95 Select Committee on Environmental Audit, supra note 56.  
96 Kaihuzi, supra note 51 at 356. 
97 Ostergard, supra note 49 at 317. 
98 Wis. Alumni Res. Foundation, supra note 53. 
99 Ostergard, supra note 49 at 317. 
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would still be able to study the protein and commercialize its use as an 
alternative sweetener. The traditional groups would not be able to claim 
j’oublie as their intellectual property under U.S. patent law or claim any 
resulting financial right to the commercial profits of third parties. 
Outside of determining public use and publication, as a naturally-
occurring substance and nucleotide sequence, even under a Chakrabarty 
framework, brazzein should not have been considered patent eligible 
material at an initial stage. The researchers at UW-Madison, similar to those 
in Myriad, simply engaged in discovery and isolation of a natural element; 
they did not invent anything markedly different from that which was already 
found in the fruit of j’oublie. Though Myriad expressly did not decide this 
scenario, perhaps once the researchers began altering the nucleotide 
sequence of brazzein to scientifically manipulate its structure and create a 
material even sweeter than that which was naturally-occurring, the result 
would be patentable both as satisfying the requirement eligible subject 
matter and the non-obviousness inventive step. However, not only does this 
invention account for less than half of the patents granted to UW-Madison, 
but furthermore, this would additionally preclude traditional groups from 
claiming a property right. First and foremost, the original and naturally-
occurring source of the sweetness would not be patentable itself and 
secondly, with the inventive step achieved by UW-Madison, traditional 
communities would not have a claim to this modification and invention. 
Overall, while the patent system might have failed in granting 
patents to UW-Madison over ineligible and naturally-occurring subject 
matter and might have been discriminatory against indigenous groups 
without written traditional knowledge prior to the passing of the AIA, the 
patent system does not offer any means by which the traditional groups could 
claim exclusive right to their traditional knowledge and genetic resources 
when it involves a naturally-occurring plant.  Even though such a case might 
constitute an immoral and wrongful taking, it is not prohibited under U.S. 
patent law. 
 
III. CASE STUDY II: IMPATIENS USAMBARENSIS  
 
Tanzania’s Usambara Mountains, located just south of Mount 
Kilimanjaro, are a “green island” rising above the surrounding dry plain and 
home to unique biodiversity, including impatiens usambarensis and 
impatiens walleriana (also known as Busy Lizzies).100  Multinational biotech 
giant Syngenta holds one utility U.S. patent101 and one patent granted by the 
E.P.O.102 for a cross between these two plant varieties, which result in a 
trailing quality. Syngenta also has a pending U.S. patent application for the 
 
100 Jay McGown, Out of Africa: Mysteries of Access and Benefit Sharing. THE EDMONDS INST. in 
cooperation with THE AFR. CTR. FOR BIOSAFETY 1, 24 (2006) (available at http://www.edmonds-
institute.org/outofafrica.pdf).  
101 U.S. Pat. No. 7,807,905 (active until 2026). 
102 Eur. Pat. No. 1711049. 
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method of crossing the two plants to result in the hybrid.103 Although 
Syngenta recognizes the trailing hybrid occurs naturally in Tanzania104 and 
that the invention relates to such plants belonging to the African group of 
ornamental impatiens,105 the company claims all trailing growth habit 
crosses of impatiens usambarensis and impatiens walleriana as its 
intellectual property including all plants,106 sexually or asexually 
produced,107 their means of reproduction—e.g. seeds,108 ovules, embryos, 
and pollen109—and even putting the floral arrangements in hanging baskets 
or other “ornamental arrangements.”110 Paralleling that of brazzein, it does 
not appear that a specific traditional community, organization, or 
government within East Africa has claimed the use of impatiens 
usambarensis as their intellectual property or specifically accused Syngenta 
of misappropriation. However, Maurizio Dioli does argue that knowing the 
scientific name of the plant used by Syngenta to create a commercial hybrid 
enabled Usambara communities to assert their rights to royalties, but Dioli 
does not disclose who, how, or when these assertions were made.111 
Syngenta does not disclose the manner by which it obtained 
impatiens usambarensis or that the plant originated in East Africa.112 In fact, 
Syngenta classifies impatiens usambarensis, the source of its claimed 
invention, Spellbound, as insignificant: “I. usambarensis is a rather robust, 
up to 2 m tall, upright growing plant which is native of the Usambara 
Mountains in Tanzania. I. usambarensis has no commercial significance.”113 
Syngenta admits the hybrids are “naturally occurring,” but claims the 
“crosses of cultivated plants generally do not yield viable seeds.”114 Though 
Syngenta discloses the procedure for crossing the plants: “In a preferred 
embodiment of the invention the naturally occurring interspecific hybrid I. 
 
103 U.S. Pat. No. 2010/0313287A1 (“A method of introgressing a trailing growth habit into a plant 
of the species Impatiens walleriana comprising the steps of…”). 
104 Tanya Wyatt, Invisible Pillaging: The Hidden Harm of Corporate Biopiracy, in Invisible Crimes 
and Social Harms 161, 166-8. (2014). 
105 U.S. Pat. No. 7,807,905 (“The instant invention relates to an Impatiens plant having a trailing 
growth habit during its vegetative and generative growth phase. The invention particularly relates to 
such plants belonging to the African group of ornamental Impatiens. The invention further relates to 
pollen, seed and sexual as well as asexual progeny of such plants, to methods for obtaining Impatiens 
plants with a trailing growth habit, to methods for propagating said plants and to uses of said plants”). 
106 See id. (“The Impatiens plant obtained by growing the seed of claim 1”). 
107 See id. (“The invention further relates to pollen, seed and sexual as well as asexual progeny of 
such plants, to methods for obtaining Impatiens plants with a trailing growth habit, to methods for 
propagating said plants and to uses of said plants”). 
108 See id. (“A seed of Impatiens line JN215, wherein a representative sample of seed was deposited 
under deposit number NCIMB 41210”). 
109 See id. (“Pollen, ovule or embryo of the plant according to claim 2”). 
110 See id. (“A specific embodiment of the invention is the use of a plant according to the invention 
for creating an ornamental arrangement in a hanging basket”). 
111 Maurizio Dioli, How to Combine Responsible Species Description, Biodiversity Protection, and 
the Activities of Amateur Botanists, 84 CACTUS AND SUCCULENT J. 233, 235-7 (2012).  
112 McGown, supra note 100 at 23.  
113 U.S. Pat. No. 7,807,905. 
114 Id. 
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usambarensis x I. walleriana is crossed with I. walleriana and sexual 
progeny of the F1 plants resulting from said cross are obtained by self-
pollination,”115 Syngenta fails to make the connection that since both parent 
plants are found as natural fauna in East Africa and are able to self-pollinate, 
the resulting hybrids are a product of nature. Indeed the crosses occur 
naturally in the Usambara Mountains, albeit rarely.  
Syngenta instead proclaims that “after many years of research” it 
has produced a variety of impatiens that “can achieve, at maturity, trails of 
70cm masses of large flowers throughout the summer until the first frost.”116 
A Syngenta representative revealed that the company obtained the seeds 
from impatiens usambarensis in 1982 from the Royal Botanic Gardens in 
Edinburgh, which had cultivated the seeds from “a wild collection from 
Tanzania.”117 Furthermore, the company admitted Syngenta paid nothing for 
the seeds: “We got them in 1990 before the international convention came 
into force. In any case our paperwork shows that when we received the seeds, 
nobody knew exactly which country they came from.”118 
Spellbound offers a great deal of commercial potential where, just 
in the U.S., impatiens represented the fourth largest annual ornamentals 
market in 2004, worth $148 million. In the UK, retail prices for Spellbound 
range from £2-£10 each.119 The Spellbound variety of impatiens also is 
lucrative on the global scale, already sold in Canada, France, Germany, and 
Italy. 120 Syngenta, itself, has provided much commercial anticipation with 
television, radio, and newspaper advertising as well as its own mascot—a 
blonde doll named Lizzie the Spellbound Fairy.121 Syngenta even sent some 
of its customers on free trips to Disney World, promoting the magical 
element of their Spellbound plant variety.122 Though the magic occurs 
naturally in the Usambaras—a pocket of endemic biodiversity rising above 
the surrounding dry landscape—the trailing growth habit indicative of the 
hybrid is highly sought after by gardeners and general consumers.123 Despite 
the popularity of impatiens walleriana, the upright nature prevented its use 
in hanging baskets, which Syngenta sought to change.124 
Syngenta, while making a profit on Spellbound, has not shared any 
benefit with the local communities of Tanzania who housed the trailing 
hybrid of impatiens as a part of their traditional knowledge and genetic 
 
115 Id.  
116 U.N. EDUC., SCI., AND CULTURAL ORG., INTERNATIONAL CONFERENCE ON BIOETHICS 
CONFERENCE PROCEEDINGS at 50 (2009) (available at 
http://unesdoc.unesco.org/images/0018/001841/184159e.pdf).  
117 Barnett, supra note 21.  
118 Id. 
119 McGown, supra note 100 at 23-4.  
120 Id. 
121 Id. 
122 Id. 
123 Id. 
124 Barnett, supra note 21. 
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resources.125 While no benefit sharing agreements have been developed with 
the country of origin, the Convention on Biological Diversity notes: “it is 
important to recognize that wild material is seldom ‘plucked’ out of the wild 
and introduced, but rather is accompanied by a long process of research and 
development—more especially where new products are involved.” 126 
However, ActionAid has a contrasting opinion, asserting: “This appears to 
be a classic case of biopiracy…Here we have a large multinational taking 
out a patent on a plant that grows naturally in a part of Africa. The Tanzania 
communities will not receive one penny.”127 
Regarding the types of misappropriation, this case study appears to 
fall squarely within the realm of ineligible and naturally-occurring subject 
matter. Whereas the researchers studying brazzein eventually engaged in a 
process that might have constituted an inventive step and resulted in a 
material, perhaps, markedly different than that which was found in nature; 
here, it is very clear that hybrids claimed by Syngenta are unaltered plants. 
Thus, the patent system again seems to fail insofar as it granted a patent that 
should not have been allowed under the requirements of patentability. This 
seems especially clear since this case does not even involve isolation of a 
nucleotide sequence from the surrounding DNA, but merely plucking a plant 
from the ground and isolating it from its surrounding landscape. As with 
brazzein, even if the traditional groups managed to write down their 
knowledge and even if this case occurred post-AIA such that public use that 
occurred outside the U.S. was recognized as a patent-defeating element, 
thereby precluding Syngenta from obtaining a patent, overall, the plant is not 
patentable general and even the traditional communities would not be able 
to assert an exclusive property right. Furthermore, though the patent system 
might not offer a remedy for the misappropriation, morally it might seem 
that Syngenta should acquire prior informed consent or access and benefit 
sharing with the traditional communities. However, without a specific group 
claiming the plants and asserting misappropriation, it is difficult to determine 
that misappropriation exists.  
 
IV. CASE STUDY III:  COMBRETUM MICRANTHUM 
 
Home to the dry regions of Western Africa and in particular 
Senegal, combretum micranthum or kinkéliba is a familiar plant harvested 
for use in tea and medicine.128 The plant is well-known among traditional 
 
125 U.N. Educ., Sci., and Cultural Org., supra note 116 at 50. 
126 ASIA-PACIFIC ECON. COOPERATION, SEMINAR ON GENETIC RESOURCES AND PROTECTION OF 
TRADITIONAL KNOWLEDGE ACCESS AND BENEFIT-SHARING IN PRACTICE: TRENDS IN 
PARTNERSHIPS ACROSS SECTORS 18 (2008) (available at 
http://mddb.apec.org/Documents/2008/IPEG/SEM2/08_ipeg_sem2_015.pdf). 
127 Barnett, supra note 21.  
128 Edward Hammond, Biopiracy Continues: A Compilation of Some Recent Cases, Third World 
Network 1, 10 (2013) (available at 
http://www.twn.my/title2/biotk/misc/Biopiracy%20Compilation_10%20Dec2012.doc).  
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groups of West Africa for its use in food and pharmacopeia, 129 and widely 
regarded for a myriad of purposes ranging from tea, to treating fevers, to 
assisting in weight loss, to managing diabetes.130 Rutgers University holds 
one U.S. utility patent,131 one Canadian patent,132 and one patent granted by 
the E.P.O.133 claiming several chemicals isolated from kinkéliba leaves that 
have potential use as anti-diabetic agents.134 Rutgers also holds a pending 
U.S. patent application135 claiming the extracted compounds medicinal uses 
in the treatment of hepatitis C virus, which causes persistent liver infections 
and affects an estimated 170-200 million people worldwide.136 Rutgers 
proclaims, “Scientists have developed a proprietary method of extracting and 
purifying a novel type of piperidine flavan alkaloids from the leaves of 
Combretum micranthum (kinkéliba) and a procedure for the preparation of 
total piperidine flavan alkaloids (TPFA) that possess anti-diabetic 
properties.”137 Paralleling that of the previous two case studies, it does not 
appear that a specific traditional community, organization, or government 
within West Africa claimed the use of combretum micranthum as their 
intellectual property or specifically accused Rutgers of misappropriation.  
While Rutgers concedes much of the plant’s role in the traditional 
knowledge of Senegal communities, Rutgers asserts the application to 
diabetes is novel and subject to patentability.138 Rutgers acknowledges, 
“Kinkéliba is a highly regarded medicinal plant in Africa, with roots, bark, 
fruit and leaves being used…[i]n its native Sub-Saharan Africa, the fresh and 
brewed leaves of kinkéliba have a long established history as being safe 
multi-functional agents that are consumed regularly for a broad range of 
health, prophylactic, curative, and anti-disease benefits.”139 Furthermore, 
Rutgers recognizes, “Combretum is the largest genus with 350 spp. and is 
widely used in traditional African medicine.” 140 Additionally: 
 
129 WORLD INTELLECTUAL PROPERTY ORGANIZATION, ASSEMBLIES OF MEMBER STATES OF WIPO 
GENERAL REPORT 1, 79 (2015) (http://www.wipo.int/edocs/mdocs/govbody/en/a_54/a_54_13.doc). 
130 Hammond, supra note 128 at 11.  
131 U.S. Pat. No. 8,642,769. 
132 Can. Pat. No. 2798509. 
133 Eur. Pat. No. 2566326. 
134 U.S. Pat. No. 8,642,769 (“A piperidine-flavan alkaloid compound of formula…” and “11. A 
pharmaceutical composition derived from a species of the kinkéliba (Combretum micranthum) 
family, the composition comprising at least one piperidine-flavan alkaloid compound of 
formula…”). 
135 U.S. Pat. No. 2013/0302279. 
136 Id. (“The present invention relates to a novel use of any one of the naturally occurring plants, 
mushrooms, plant and mushroom extracts, and specific polyphenols or alkaloids that exhibit 
properties as HCV NS5B polymerase inhibitors.”) 
137 Rutgers University, Anti-Diabetic Agents from Leaves of Combretum Micranthum Rutgers 
University, (last visited Apr. 6, 2017) (available at  
http://techfinder.rutgers.edu/tech/Anti-
Diabetic_Agents_from_Leaves_of_Combretum_micranthum_(Kinkeliba)).  
138 Hammond, supra note 128 at 11. 
139 Rutgers University, supra note 137. 
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Combretum micranthum is an ethnomedicinal plant widely used in 
West Africa to treat many diseases. In traditional medicine, 
kinkéliba is used for the treatment of wounds and sores, guinea 
worm infestations, diuretic and digestion [1, 3-5]. In the fresh form, 
the leaves are used to reduce fevers, especially malaria fever [3, 4, 
6] and as anti-inflammatory agent [7]. The bark of C. micranthum 
has high antioxidant capacity and antibacterial activity, and this is 
directly related to its high content of polyphenolic content [8]. It is 
reported that kinkéliba branches are used in local handicraft and are 
an important material for building material for stools, beds, tool 
handles, etc. [9]. A tea, made from steeping the leaves in boiling 
water, is a traditional tonic drink in tropical savannah countries such 
as Senegal, Mali and Burkina Faso and it is believed to be a general 
aid to weight loss and has detoxifying properties and ‘healthy 
benefits.’141 
 
However, despite all the knowledge and use of kinkéliba by traditional 
groups of West Africa, Rutgers argues “there is no specific information 
confirming any application nor any studies documenting its validity and/or 
underlying reason for its purported uses” and that the compound “has not 
been systematically studied to determine its origin at a molecular or chemical 
constituent level.”142 Thus, Rutgers’ purported invention “represents such an 
effort to fulfill the foregoing need based on the discovery that kinkéliba tea 
possesses an interesting anti-diabetic effect, which could be a combination 
of glucose-lowering and weight loss effects when the tea is used in a 
traditional manner.”143 Rutgers’ invention, at least in part, intends to validate 
uses of the compound already known in traditional medicine. 
The remaining intent behind the invention purports to exploit new 
bioactive compounds for development as new therapeutic agents for the 
treatment of diabetes.144 In a novel regard, Rutgers declares, “Our scientists 
have identified and isolated specific compounds from kinkéliba leaves that 
result in a significant glucose-lowering functionality and can be 
administered in efficacious dosages as a dietary supplement or food 
additive.”145 Rutgers cites animal studies involving the isolated compounds 
of Combretum micranthum, which demonstrate “decreased fasting plasma 
glucose levels, increased glucose tolerance, lower plasma insulin levels”, 
decreased liver expression of a gene indicating antidiabetic activity, and anti-
 
141 Id. 
142 Id. 
143 U.S. Patent No. 8,642,769 (“In another aspect the present invention relates to validation of some 
use of the plants in traditional medicine”). 
144 U.S. Patent No. 8,642,769 (“In another aspect the present invention sought to identify the 
structures of the novel bioactive compounds. In another aspect the present invention sought to exploit 
these new compounds for the development of new therapeutic agents for treatment of diabetes and/or 
other diseases or disorders”). 
145 Rutgers University, supra note 137. 
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inflammatory action.146 To be sure, these findings suggest vast medicinal 
implications and commercial application for treatment of “diabetes, 
metabolic disorders, [and] weight loss.”147 Rutgers also lists several 
advantages to using kinkéliba including that it has been well documented as 
a as a safe medical use, has an established safety profile, is a readily available 
source, is rich in antioxidants, and has distinct attributes and functionality as 
compared to other common teas.148 The claim of kinkéliba as a readily 
available source is particularly troubling since it seems to suggest continued 
access and taking of the plant from the natural landscape home to the 
traditional communities. This not only ensures continued misappropriation 
of the original genetic resource, but could compromise biodiversity in the 
area. It would seem much of the advantages stem from having a long history 
of use as traditional knowledge with the indigenous communities to that 
region.  
However, it is this trait which theoretically precludes Rutgers from 
asserting an intellectual property right. Indigenous groups have long been 
aware and have utilized kinkéliba as a treatment for diabetes prior to 
Rutgers’ patent application. Edward Hammond, in his publication on 
biopiracy, highlights one such example of indigenous use of kinkéliba 
preceding the patent application filed by Rutgers:  
For instance, in 2006, an African study on use of traditional 
remedies for diabetes was published in Diabetes & Metabolism.   
The Guinean researchers surveyed 397 diabetes patients at Conakry 
University Hospital, of whom 131 (33%) said they used traditional 
treatments. Asked to identify the plants they used, they collectively 
identified 31 species. Of these, kinkéliba was the third most 
frequently cited plant, used by 19% of the respondents.  This 
indicates that use of kinkéliba in Guinea to treat diabetes not only 
exists, but is also commonly known.149 
 
Rutgers dismisses potential concern for misappropriation of the genetic 
resource by hollowly stating its claims to intellectual property are “distinct 
from validating traditional uses and applications of medicinal plants which 
would overlap with Traditional Knowledge (TK) related issues.”150 At the 
same time, in light of this use by traditional groups, Rutgers does have a 
benefit-sharing plan. However, in this plan, Rutgers only asks that 
commercial companies licensing the University patents share benefits, but 
does not disclose its own intention to share profits with the indigenous 
peoples of the region: “As [Rutgers] does not commercialize products, but 
rather licenses the rights to commercialize an invention to a private sector 
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company, [Rutgers] requests that the private sector company must be 
committed to adhering to a benefit sharing policy based upon the 
commercialization of a patent, invention or discovery.”151 Thus, as 
Hammond argues, Rutgers’ benefit-sharing policy is essentially 
meaningless, lacking implementation and workability.152 Furthermore, the 
policy “falls short of any reasonable interpretation of compliance of either 
the Convention on Biological Diversity or its Nagoya Protocol on Access to 
Genetic Resources and the Fair and Equitable Sharing of Benefits”.153 
Regarding types of misappropriation, here, there are similar concerns 
regarding potential ineligible and naturally-occurring subject matter and 
public use outside the U.S. being irrelevant pre-AIA. However, this case 
study of kinkéliba also demonstrates a failure of the patent system to account 
for available printed publications, which should have defeated Rutgers’s 
patent claim to the use of kinkéliba for treatment of diabetes. Unfortunately, 
this is another instance of the patent system not working as the statutes 
dictate and thus, in the case that proper novelty and nonobviousness 
requirements were applied, the University as well as the traditional 
communities utilizing the medicinal qualities of kinkéliba would be 
precluded from claiming exclusive property rights. Additionally, without a 
conceivable property right given to the traditional groups and without any 
specific group claiming misappropriation, the case does not seem to fall into 
any definition of misappropriation, which requires the improper use of 
another’s property presumably when the victim claims a wrongful taking. 
 
V. RECOMMENDATIONS 
 
Importantly, the first recommendations would be to take steps to 
ensure the patent system worked correctly such that the requirements of 
eligible subject matter, novelty, and nonobviousness were properly applied 
to applications and resulted in the denial of patent grants for material that is 
naturally occurring, had been in public use, and had been published. 
Furthermore, it is crucial that the patent system is not inherently 
discriminatory against indigenous populations outside of the U.S. The 
passing of the AIA helped reverse the institutional bias by expanding public 
use as a patent-defeating element even if it occurred outside the U.S. and by 
not relying solely on international printed publications when traditional 
knowledge is rarely written. Such precautions will ensure the patent system 
does not harm the traditional groups by enabling misappropriation through 
granted patents to universities and corporations outside of the indigenous 
 
151 Rutgers University, Agreement on Benefit Sharing Policy Related to African 
and International Inventions,(last visited Apr 17, 2017) (available at 
http://www.pricklyresearch.com/webdump/Rutgers_Africa/Agreement%20on
%20Benefit%20Sharing%20Policy%20Recommended%20by%20NUANPP%
20at%20Rutgers%20Related%20to%20African%20or%20International%20Inv
entions.pdf). 
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populations. However, if such material is unpatentable by other entities, the 
material will also be unpatentable by the traditional communities as well. 
Thus, the patent system must be transformed in such a way as to protect the 
traditional knowledge and genetic resources of indigenous groups. Not only 
must wrongful patents to other entities be defeated, but for the traditional 
communities, patents must be enabled. Furthermore, simple procedures such 
as required disclosure of sources, mechanisms to spread awareness, written 
and searchable libraries of traditional knowledge, acknowledgement of 
property rights, prior informed consent, and access and benefit sharing 
agreements would help safeguard the knowledge and prevent wrongful 
misappropriation. 
Maurizio Dioli, in his journal article How to combine responsible 
species description, biodiversity protection, and the activities of amateur 
botanists, argues it was the revelation of the scientific name—impatiens 
usambarensis—which enabled the indigenous communities to assert their 
rights to the royalties.154 Masked behind the commercial name 
“Spellbound,” the alleged misappropriation is unknown not only to 
consumers buying the products, but to the very victims of biopiracy. Dioli 
further emphasizes: “Undescribed species are therefore of significant 
advantage for large bio-engineering firms because they allow exploitation of 
a specific substance produced by or genetic trait of a plant, claiming it to be 
the work of their own research or to be of unknown identity and origin.”155 
Additionally, unknown sourcing prevents indigenous communities from 
receiving future royalties and from asserting property rights in litigation 
proceedings without “corpus delicti” or proof of crime.156  
Regarding a potential solution to such a predicament, Dioli suggests 
botanical knowledge and identification of scientific species are crucial for 
documenting the chain of research.157 Not only does this hold corporations 
and researchers accountable for the plants acquired and studied, but it 
furthermore, allows indigenous communities to recognize their genetic 
resources and assert a property right. At the same time, indigenous groups 
often are unaware of the scientific name for a species of plant as they are 
regarding a corporation’s commercial trademark. To this end, Dioli argues it 
is amateur botanists—free to travel to remote locations off-limits to official 
botanists—that “are the only practical tool available that could help the 
official botanical institutions of such countries to rapidly and inexpensively 
increase their botanical knowledge and simultaneously limit bio-piracy.”158 
As an example, since 2000, amateur botanists have discovered well over 
60% of all new aloe taxa.159 
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At an Assembly of the Member States of WIPO, the Delegation of 
Guinea spoke of their immense repertoire of traditional knowledge, genetic 
resources, and folklore, which must “be promoted within a regulated 
framework in order to enable access thereto and share the benefits arising 
from related exploitation.”160 Both the Access and Benefit-Sharing Capacity 
Development Initiative and the Nagoya Protocol to the Convention on 
Biological Diversity vocalize a similar concern, recognizing the 
misappropriation suffered by Guinea.161 Traditional knowledge, which once 
held a vital share of the national economy in their corresponding countries, 
had been “endangered” due to a lack of regulatory and intellectual property 
protection.162 The Delegation offered combretum micranthum as exemplary 
of the international property system failing—where local communities had 
utilized for generations the genetic resource for the very same medicinal 
properties that Rutgers sought to commercially exploit.163 The Delegation 
contemplated:  
If that trend continued unchecked, indigenous communities in 
Guinea would be gradually stripped of their property without 
recompense, hence the urgent need to define appropriate 
international mechanisms allowing for the rational exploitation of 
those resources for the benefit of the communities which owned 
them, with a view to contributing to poverty reduction and 
alleviating rural exodus.164 
 
To reconcile this problem, the Delegation suggests a 2015 convention on 
traditional knowledge, genetic resources, and folklore like that held in the 
United Republic of Tanzania in 2013.165 The Tanzanian conference 
“contributed significantly to increasing awareness among senior decision 
makers of the need to invest in intangible assets for the development of a 
knowledge based economy.”166 Similarly, the Delegation hopes to adopt a 
binding international legal instrument for protection of its intellectual 
property.167 
As Kofi Busia notes, in his journal article titled Overview of Traditional 
Medicine in the Economic Community of West African Member States, 
traditional medicine is the main source of healthcare for the indigenous 
peoples of West Africa with estimates that between 70-80% of West 
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Africans use traditional medicine to manage disease. 168 Unfortunately, 
insufficient political and legal infrastructure and regulation perpetuates 
health disparities among the native populations. Busia highlights that 
intellectual property, as a relatively new concept, “delays the development 
of frameworks for the protection of traditional knowledge and access to 
biodiversity in majority of Member States.”169 Busia outlines the results of a 
situational analysis conducted by the West African Health Organization 
intended to assess the level of development of traditional medicine in the 
Member States: 
In the sub-Region, Cote d'Ivoire carried out a survey among 
[traditional medicine practitioners] that has recorded more than 
2,000 traditionally used plants. In 2007, Ghana developed a national 
policy on protection of [intellectual property rights] which was 
reviewed in 2008. In 2006 and 2007 Nigeria developed national 
legislation and Bill on [intellectual property rights] whereas Mali 
organized a series of national and sub-Regional workshops for the 
protection of traditional medical knowledge... Ghana developed a 
database on Ethnobotanical Floristic Studies and Traditional 
Medicine Pharmacopoeia in 2000 and Senegal developed a database 
of THPs in 2003. Benin and Mali reported to have established in 
1999 and 2004 databases related to 7,500 THPs and [traditional 
medical knowledge] and access to biological resources respectively. 
170 
 
It is the dissemination of information, the accessibility and consolidation, as 
well as the legal protection and regulatory frameworks needed to safeguard 
traditional knowledge and genetic resources. Busia explains, this is an area 
“where WAHO will collaborate with WHO…to support member states 
develop national policies and regulatory frameworks, carry out national 
inventories of medicinal plants to ensure that indigenous knowledge is used 
correctly and continuously over generations, obtain patents protection, [and] 
establish databases…to document formulations used in traditional medicine 
to prevent misappropriation.”171 Taking inspiration from India, documenting 
an indigenous groups’ traditional knowledge and genetic resources in a 
forum accessible internationally is the first step to preventing 
misappropriation insofar as it serves as an assertion to their property right.  
However, databases put the responsibility of the disclosure on the indigenous 
groups who are often less technologically and financially capable and may 
prevent later patentability due to the disclosure and documented public use.  
Furthermore, as the three case studies demonstrate, corporations and 
universities are quick to not only devalue the original source of their research 
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even in the rare instances where sourcing is disclosed, but additionally, the 
entities tend to express entitlement to the study of the natural materials. 
While the corporations and universities clearly recognize at least some use 
by the traditional groups, which would indicate the sweetness, trailing 
qualities, or medicinal properties of plants a part of their traditional 
knowledge and genetic resources, the corporations and universities do not 
suggest that these materials and uses are thereby the property of the 
traditional groups. Not only does this mentality prevent external entities from 
seeking prior informed consent by the traditional communities for use of 
their property, but it also seems to eliminate any perceived responsibility to 
engage in benefit-sharing with the original holders of the traditional 
knowledge and genetic resources. Acknowledgement of any property right 
by the indigenous groups, whether or not it may be patentable, is a large step 
in preventing misappropriation. 
Finally, aside from failure of the patent system to: properly apply limitations 
of ineligible subject matter to naturally-occurring materials, recognize public 
use outside of the U.S. pre-AIA as a means to defeat novelty, thoroughly 
search printed publications of traditional groups and studies outside of the 
U.S. where such use and knowledge is disclosed by the written word—these 
shortcomings merely render the material unpatentable to both universities 
and corporations as well as the traditional communities themselves. In order 
to prevent misappropriation on a larger scale and allow traditional groups to 
have their own claims to their property, elements of traditional knowledge 
and genetic resources should not only be patent defeating, but patent 
enabling for those who have knowledge of and are engaged in its use. The 
conclusions of these case studies should not be that no property right exists 
and the information is already within the public realm, but rather that the 
knowledge and use belongs to the traditional groups that harbor the materials 
and knowledge as a part of their identity. 
 
CONCLUSION 
 
Under Lewinski’s definition, none of the case studies discussed 
would fall within the parameters of misappropriation; all three revolve 
around natural and unpatentable material incapable of misappropriation and 
not deserving of an intellectual property right, which requires novelty, 
nonobviousness, and something markedly different than that occurring in 
nature. This distinction parallels the rights acknowledged by the U.S. patent 
system.  
While all the case studies highlight a failure of the patent system to 
correctly apply its requirements and instead resulted in the granting of 
patents over unpatentable material, overall, the patent system would not 
recognize any property right over the information: impatiens usambarensis, 
falls squarely within the definition of ineligible subject matter as naturally-
occurring plant; combretum micranthum should have been unpatentable due 
to a disclosure of its anti-diabetic use in a printed publication; 
pentadiplandra brazzeana perhaps with the most research, development, and 
isolation might fall within the parameters of a property right if looking at the 
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changes to the amino acid sequence, but might even surpass 
misappropriation if deemed novel and markedly different from that 
occurring in nature such that the traditional communities would still be 
unable to lay meaningful claim to the invention. Since misappropriation 
entails the improper use of information belonging to another and the 
indigenous communities lack any property right, these case studies would 
not fall into definitions of misappropriation that are not sensitive to the 
particularities of traditional knowledge. Even if the patent system had not 
misapplied its requirements and had not granted patents to third parties, the 
corporations and universities would have still been able to commercialize 
the information without a property right by the traditional communities. 
While such exploitation of the knowledge might not be prohibited under 
patent law and might not constitute certain understandings of 
misappropriation, as Lewinski acknowledged, the taking is still wrongful 
and immoral—it is theft. 
Though the patent system has made significant changes to 
infrastructure so as to not entail inherent discrimination against indigenous 
populations outside the U.S., the system still has many shortcomings. 
Fortunately, with the passing of the AIA, public use outside of the U.S. is 
now recognized under patent law and serves as novelty-defeating element. 
This allows indigenous groups to invalidate patents granted to third parties 
without having to rely on printed publications when traditional knowledge is 
predominately oral. However, such public use over the course of centuries—
as is required by the definition of traditional knowledge—also defeats the 
indigenous groups’ claim to a property right over the information. 
Furthermore, traditional knowledge is rarely manipulated to produce 
something markedly different from that found in nature; as ineligible subject 
matter, the patent system precludes the patentability of nearly all genetic 
resources. Additionally, once a third party transforms the information into 
something patentable, something markedly different from that occurring in 
nature, the property right belongs only to the researchers. Without any 
property right recognized by the indigenous groups, use of the information 
is not misappropriation under patent law and there need not be licensing 
agreements or other compensation. 
Thus, the patent system must not only help to defeat patents which claim 
elements of traditional knowledge, but the patent system must be reorganized 
so as to enable the patentability of traditional knowledge by the traditional 
groups despite the limitations of public use, printed publications, novelty, 
nonobviousness, and ineligible subject matter. Morality dictates that 
traditional groups have some avenue to either claim the property right or 
have some combination of benefit sharing, informed consent, or recognition 
of their contribution. 
 
 
